# A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.

> **NCT07462468** · PHASE1 · NOT_YET_RECRUITING · sponsor: **WestVac Biopharma Co., Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Platinum-resistant Recurrent Ovarian Cancer (PROC)

## Interventions

- **DRUG:** WSK-IM02
- **DRUG:** WSK-IM02

## Key facts

- **NCT ID:** NCT07462468
- **Lead sponsor:** WestVac Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-10
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-09-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07462468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07462468, "A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT07462468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*